Tecentriq could be more than an also-ran in SCLC, says GlobalData

Roche’s (ROG: SIX) immuno-oncology drug Tecentriq (atezolizumab) has largely been an outsider to the leaders in the first wave of I-O treatments, Bristol-Myers Squibb’s (NYSE: BMY) Opdivo (nivolumab) and Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab).

But according to new analysis from the data and analytics company GlobalData, the planned submission of Tecentriq for prospective marketing approval in the USA and Europe by Roche could put the Swiss pharma giant in a very strong position within the small cell lung cancer (SCLC) treatment space.

This follows the news that Roche’s Phase III IMpower133 study evaluating Tecentriq with carboplatin and etoposide, the standard-of-care chemotherapy regimen in treatment-naïve extensive-stage small cell lung cancer (ES-SCLC), met its co-primary endpoints of overall survival and progression-free survival at the first interim analysis.